Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry News Roundup

This article was originally published in The Tan Sheet

Executive Summary

Speech supplement firm stifled; Botanical Adulterants Program guidance debuts; Fruitful supplements, app launch; Bulu partners with bug protein firm; Healthy Mama extends line; Unilever acquires P&G’s Camay; demand soars for prebiotic infant food supplement; Axiom adds facility, appoints medical board chief; Kefir national ads debut during Golden Globes; and direct selling veteran heads foru.

You may also be interested in...



In Brief: laxatives warning, FTC settlement, ChromaDex inks 5LINX deal

Sodium phosphate laxatives linked to SAERs; FTC scrutinizes personalized supplement claims; NAD refers Xlear LLC to FTC; ChromaDex inks marketing deal with 5LINX; CVS launches vitamin sales, info hub on its website; Star Scientific shareholder suit proceeds.

Industry Herbal Adulterants Program Seeks To Simplify Detection

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Topics

Related Companies

UsernamePublicRestriction

Register

PS107433

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel